Skip to content
Open access

Integrative Nutrigenomic Systems Biology Analysis of Traditional Chinese Medicine Interventions in Parkinson’s Disease: Nutrient-Gene-Disease Network Perspectives

Aug 2026 · OBM Genetics · 0 citations · 61 references

TL;DR

The combined model finds a mutual dysregulation of epigenetics and microRNA as the main cause of gene silencing, illustrating a neuro-nutrigenomic application in which dietary-derived and herbal compounds may modulate gene expression and epigenetic marks in Parkinson's disease.

Abstract

The pathology of PD is characterized by progressive degeneration of dopaminergic neurons, although the full regulatory network involved in this process is not yet fully established. The present research employed a multi-omic systems biology design, integrating transcriptomic, functional, epigenetic, and microRNA analyses to develop a mechanistic model of neurodegeneration in the substantia nigra. We have determined six differentially expressed genes, such as tyrosine hydroxylase (TH), solute carrier family 18 member 2 (SLC18A2/VMAT2), and engrailed 1 (EN1), that are of critical interest in the disruption of the dopaminergic synapse and the inability to load vesicular neurotransmitters (fold enrichment: 2164.22). Notably, we have identified a candidate dual regulatory axis underlying the silencing of these neuroprotective genes. In this mechanism, repressive histone marks (H3K27me3 and H3K9me3) are concurrent, and post-transcriptional repression via specific microRNAs, in particular, hsa-miR-431-3p (EN1) and mmu-miR-362-5p (SLC18A2), is involved. The combined model thus finds a mutual dysregulation of epigenetics and microRNA as the main cause of gene silencing. Besides, the Traditional Chinese Medicine (TCM) components were analyzed to identify compounds that can interact with the core targets (TH and SLC18A2), thereby providing translational potential. The results identify candidate TCM compounds predicted to interact with core targets (TH and SLC18A2), providing hypothesis-generating leads for multi-target interventions that may modulate the repressive epigenetic landscape, suppress regulatory microRNAs, and engage dopaminergic pathways. Predicted interactions require experimental validation to distinguish beneficial modulation from potential inhibition. This would seek to reverse severe neuronal activity and halt the advancement of Parkinson's disease. These findings illustrate a neuro-nutrigenomic application in which dietary-derived and herbal compounds may modulate gene expression and epigenetic marks in Parkinson’s disease.

Read PDF

Similar papers

Review Open access Aug 2026

MicroRNA-phytochemical interactome targeting thioredoxin-interacting protein: a narrative review at the nexus of RNA therapeutics, cancer biology, and metabolic regulation

This narrative review discussed emerging trends on phytochemical-mediated regulation of TXNIP-associated miRNAs, including miR-148b, miR-33a/b, miR-17-5p, miR-224, and miR-20a, with particular emphasis on the conserved miRNA seed region as the principal determinant of target recognition.

Peter Chinedu Agu, P. Aja, C. Ofor et al. · 0 citations
Jul 2026

Systems pharmacology and targeted transcriptional profiling suggest the putative neuroprotective role of Leuconostoc mesenteroides in an in vitro Alzheimer’s disease model

A theoretical Phytoene-PPAR-APOE signaling axis as a predictive framework for the observed cellular effects is suggested and it is emphasized that phytoene represents a predicted candidate metabolite requiring future chemical characterization and biological validation.

Safaa Altveş, Ebru Guclu, Esra Yetisgin et al. · 0 citations
Open access Jul 2026

Identification of divergent organ-specific gene and protein expression signatures for mitochondrial function, inflammatory response, and proteostasis in the liver and brain in the rotenone-induced rat model of Parkinson’s disease

Tissue-specific molecular associations in the liver and brain within the ROT-induced PD model are demonstrated, providing new insights into the pathophysiology of neurodegeneration and identifying potential biomarkers and therapeutic targets for future studies.

Tuba Oz, Juan Fraile-Ramos, Radosław Kujawski et al. · 0 citations
Review Open access Jul 2026

Epigenetic Regulation in Parkinson’s Disease: Cutting -Edge Insights into miRNAs, lncRNAs and Chromatin Modifiers

Current insights into the roles of miRNAs, lncRNAs, and chromatin modifiers in Parkinson’s disease are critically summarized, their potential as biomarkers and therapeutic targets are discussed, and key challenges and future perspectives in translating epigenetic discoveries into clinical applications are highlighted.

Sumithira George, Sivakumar Subramaniyan, Mukesh Rajagopal et al. · 0 citations
Open access Aug 2026

Integrative Multi-Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease.

An integrative multi-omics reanalysis of single-cell transcriptomic and epigenomic data to identify convergent alterations predisposing dopaminergic neurons to degeneration in Parkinson's disease and to generate new bulk ATAC-seq profiles from peripheral monocytes to assess whether these alterations extend to a systemi...

Mirco Macchi, A. Ginolhac, Tony Heurtaux et al. · 0 citations
Review 2026

Genetic and epigenetic complexity of Parkinson's disease: From dopamine pathways to estrogen interplay.

This chapter integrates recent advancements by linking mechanistic insights to translational potential, focusing on epigenetic biomarkers and disease-modifying techniques designed to restore lysosomal function, rectify dopamine processing, and strategically exploit hormone pathways.

K. Deena, Lakshman Nathish, Er Antony Fenwick et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.